ReportsnReports | Chemotherapy-Induced Neutropenia (CIN) Therapeutics –Pipeline Assessment and Market Forecasts to 2018 GlobalData, the industry analysis specialist, has released its new report, “Chemotherapy-Induced Neutropenia (CIN) Therapeutics –Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global CIN therapeutics market. The report identifies the key trends shaping and driving the global CIN therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global CIN sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. GlobalData estimates that the global Chemotherapy-induced Neutropenia (CIN) therapeutics market was valued at $3.6 billion in 2005 and grew at a Compound Annual Growth Rate (CAGR) of 5.8% to reach $4.8 billion in 2010. The market is forecast to grow at a CAGR of 2.3% over the next eight years to reach $5.8 billion by 2018. This decline in growth rate is primarily attributed to the expected patent expiry of Neupogen in 2013 (2006 in Europe) and Neulasta in 2015 which will make way for the entry of biosimilars (generic version of biologics) into the market. The increase in prescription population will help in partially offsetting the revenue loss due to the patent expiries. Note: This is a on-demand report and will be delivered within 3 business days of the purchase (excluding weekends). Scope The report provides information on the key drivers and challenges of the CIN market. Its scope includes - Analysis of seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan), with CIN market revenues data from 2005 to 2010, and forecasts to 2018. - Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as long acting recombinant PEGylated G-CSFs, long-acting recombinant human albumin-G-CSFs, long acting glyco-PEGylated recombinant human G-CSFs, long-acting recombinant GM-CSFs, allogeneic cell-based therapies, recombinant fusion protein G-CSFs, neutrophil stimulators, recombinant protease inhibitors and hematopoeitic stem cell stimulators. - Analysis of the current and future competition in the global CIN therapeutics market. Key market players covered are Eurofarma Laboratorios Ltda, Green Cross Corporation in collaboration with Symyoo, Intas Biopharmaceuticals Ltd. in collaboration with Apotex Inc. and Teva Pharmaceuticals. - Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. - Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the CIN therapeutics market. - Analysis of key recent licensing and partnership agreements in CIN therapeutics market Reasons to buy The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. - Develop business strategies by understanding the trends shaping and driving the global CIN market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global CIN therapeutics market in future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. - What’s the next big thing in the global CIN therapeutics market landscape? – Identify, understand and capitalize. Table of Contents 1 Table of Contents 2 1.1 List of Tables 5 1.2 List of Figures 6 2 Chemotherapy-Induced Neutropenia (CIN) Therapeutics: Executive Summary 8 2.1 The CIN Therapeutics Market is Forecast to Show Slow Growth Until 2018 8 2.2 The CIN Therapeutics Market has Significant Unmet Need in Terms of Cost-Effectiveness 9 2.3 CIN Developmental Pipeline Lacks Novelty and is Crowded with Biosimilars 10 2.4 Entry of Biosimilars in the CIN Therapeutics Market 11 3 Chemotherapy-Induced Neutropenia (CIN) Therapeutics: Introduction 12 3.1 Overview 12 3.1.1 Classification of CIN 16 3.1.2 Febrile Neutropenia 17 3.2 Epidemiology 17 3.3 Symptoms 17 3.4 Etiology 18 3.5 Pathophysiology 18 3.6 Risk factors for CIN 19 3.7 Diagnosis 23 3.8 Treatment of CIN 24 3.9 GlobalData Pipeline Report Guidance 31 4 Chemotherapy-Induced Neutropenia (CIN) Therapeutics: Market Characterization 32 4.1 CIN Therapeutics Market Size (2005-2010) – Global 32 4.2 CIN Therapeutics Market Forecast (2010-2018) – Global 34 4.3 CIN Therapeutics Market Size (2005-2010) – The US 36 4.4 CIN Therapeutics Market Forecast (2010-2018) – The US 37 4.5 CIN Therapeutics Market Size (2005-2010) – France 38 4.6 CIN Therapeutics Market Forecast (2010-2018) – France 41
4.7 CIN Therapeutics Market Size (2005-2010) – Germany 43 4.8 CIN Therapeutics Market Forecast (2010-2018) – Germany 45 4.9 CIN Therapeutics Market Size (2005-2010) – Italy 47 4.10 CIN Therapeutics Market Forecast (2010-2018) – Italy 49 4.11 CIN Therapeutics Market Size (2005-2010) – Spain 51 4.12 CIN Therapeutics Market Forecast (2010-2018) – Spain 53 4.13 CIN Therapeutics Market Size (2005-2010) – The UK 55 4.14 CIN Therapeutics Market Forecast (2010-2018) – The UK 57 4.15 CIN Therapeutics Market Size (2005-2010) – Japan 59 4.16 CIN Therapeutics Market Forecast (2010-2018) – Japan 60 4.17 Drivers and Barriers for the CIN Therapeutics Market 62 4.17.1 Drivers for the CIN Therapeutics Market 62 4.17.2 Barriers for the CIN Therapeutics Market 63 4.18 Key Events Impacting the Future Market 64 4.19 Opportunity and Unmet Need Analysis 64 4.19.1 Key Takeaway 66 5 Chemotherapy-Induced Neutropenia (CIN) Therapeutics: Competitive Assessment 68 5.1 Overview 68 5.2 Strategic Competitor Assessment 68 5.2 Product Profile for the Major Marketed Products in the CIN Therapeutics Market 70 5.2.1 Neulasta (pegfilgrastim) 70 5.2.2 Neupogen (filgrastim) 71 5.2.3 Leukine (sargramostim) 72 5.2.4 Granocyte/ Neutrogin (lenograstim) 73 5.3 Key Takeaway 75 6 Chemotherapy-Induced Neutropenia (CIN) Therapeutics: Pipeline Assessment 76 6.1 Overview 76 6.2 Strategic Pipeline Assessment 76 6.2.1 CIN Therapeutics – Pre-registration Pipeline 77 6.2.2 CIN Therapeutics – Phase III Pipeline 77 6.2.3 CIN Therapeutics – Phase II Pipeline 78 6.2.4 CIN Therapeutics – Phase I/II Pipeline 78 6.2.5 CIN Therapeutics – Phase I Pipeline 78 6.2.6 CIN Therapeutics – Preclinical Pipeline 78 6.3 CIN Therapeutics – Pipeline by Mechanism of Action 79 6.4 CIN Technology Trends Analytical Framework 80 6.5 Molecule Profile for Promising Drugs under Clinical Development 81 6.5.1 Neugranin 81 6.5.2 Lipegfilgrastim (XM22) 82 6.5.3 Filgrastim 82 6.5.4 Neukine 82
6.5.5 GCPGC 83 6.6 Key takeaway 83 7 Chemotherapy-Induced Neutropenia (CIN) Therapeutics: Clinical Trials Mapping 84 7.1 Clinical Trials by Region/Country (the US, EU5 and Japan) 84 7.2 Clinical Trials by Phase 85 7.3 Clinical Trials by Status 86 7.4 Overall Sponsors 86 7.5 Prominent Sponsors 87 7.6 Participants in Therapeutic Clinical Trials – Companies 88 8 Chemotherapy-Induced Neutropenia (CIN) Therapeutics: Strategic Assessment 90 8.1 CIN Therapeutics: Implications for Future Market Competition 90 9 Chemotherapy-Induced Neutropenia (CIN) Therapeutics: Future Players 93 9.1 Introduction 93 9.2 Company Profiles 93 9.2.1 Teva Pharmaceutical Industries Limited 93 9.2.2 Eurofarma Laboratorios Ltda. 95 9.2.3 Green Cross Corporation 96 9.2.4 Intas Biopharmaceuticals Ltd. 96 9.2.5 Apotex Inc. 97 10 Chemotherapy-Induced Neutropenia (CIN) Therapeutics: Appendix 99 10.1 Definitions 99 10.2 Acronyms 99 10.3 Research Methodology 100 10.3.1 Coverage 101 10.3.2 Secondary Research 101 10.3.3 Forecasting 101 10.3.4 Primary Research 104 10.3.5 Expert Panel Validation 105 10.4 Contact Us 105 10.5 Disclaimer 105 10.6 Bibliography 106 Latest Market Research Reports: Annual Forecasting Food & Grocery 2015 Global Small and Medium Scale LNG Industry Outlook to 2015 Offshore Wind Industry – Growth Potential Hampered by Issues in Supply Chain and Financing Crohn’s Disease (CD) Therapeutics – Pipeline Assessment and Market Forecasts to 2018 Drug Eluting Balloons (DEB) – Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 Austria Power Market Outlook to 2030 – Business Propensity Indicator (BPI), Market Trends, Regulation and Competitive Landscape Angina Pectoris Therapeutics – Pipeline Assessment and Market Forecasts to 2018
Bronchitis Therapeutics- Pipeline Assessment and Market Forecasts to 2018 About Us: ReportsnReports.com is an online market research library of 135,000+ reports and in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers. Visit http://www.reportsnreports.com/ for more details. Contact: Priyank Tiwari 7557 Rambler road, Suite 727, Dallas, TX 75231 Tel: +1-888-391-5441 sales@reportsandreports.com Visit our Market Research Blog @ http://www.reportsnreportsblog.com/ Connect with us on: Twitter @ http://www.twitter.com/marketsreports Facebook @ http://www.facebook.com/pages/ReportsnReports/191441427571689 LinkedIn @ http://www.linkedin.com/company/reportsnreports